Readoutin 76d
Pfizer — PF-06821497
Phase 3 primary completion: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)..
- Date
- Feb 2027
- Type
- Readout
- Indication
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)